Literature DB >> 14645982

Burkholderia pseudomallei: another emerging pathogen in cystic fibrosis.

M R O'Carroll1, T J Kidd, C Coulter, H V Smith, B R Rose, C Harbour, S C Bell.   

Abstract

BACKGROUND: Burkholderia pseudomallei is an important cause of acute fulminant pneumonia and septicaemia in tropical regions of northern Australia and south east Asia. Subacute and chronic forms of the disease also occur. There have been three recent reports of adults with cystic fibrosis (CF) who presumably acquired B pseudomallei infection during extended vacations or residence in either Thailand or northern Australia.
METHODS: The clinical course, molecular characteristics, serology and response to treatment are described in four adult CF patients infected with B pseudomallei. Polymerase chain reaction (PCR) based methods were used to confirm B pseudomallei and exclude B cepacia complex. Genotyping was performed using randomly amplified polymorphic DNA (RAPD) PCR and pulsed field gel electrophoresis (PFGE).
RESULTS: Four patients are described with a mean duration of infection of 32 months. All but one patient lived in tropical Queensland. Two patients (with the longest duration of infection) deteriorated clinically and one subsequently died of respiratory failure. Both responded to intravenous treatment specifically targeting B pseudomallei. Another patient suffered two severe episodes of acute bronchopneumonia following acquisition of B pseudomallei. Eradication of the organism was not possible in any of the cases. PFGE of a sample isolate from each patient revealed the strains to be unique and RAPD analysis showed retention of the same strain within an individual over time.
CONCLUSIONS: These findings support a potential pathogenic role for B pseudomallei in CF lung disease, producing both chronic infection and possibly acute bronchopneumonia. Identical isolates are retained over time and are unique, consistent with likely environmental acquisition and not person to person spread. B pseudomallei is emerging as a significant pathogen for patients with CF residing and holidaying in the tropics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14645982      PMCID: PMC1746554          DOI: 10.1136/thorax.58.12.1087

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  22 in total

1.  Achieving 100% typeability of Pseudomonas aeruginosa by pulsed-field gel electrophoresis.

Authors:  U Römling; B Tümmler
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

2.  Arabinose assimilation defines a nonvirulent biotype of Burkholderia pseudomallei.

Authors:  M D Smith; B J Angus; V Wuthiekanun; N J White
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

3.  Imported melioidosis in England and Wales.

Authors:  D A Dance; M D Smith; H M Aucken; T L Pitt
Journal:  Lancet       Date:  1999-01-16       Impact factor: 79.321

4.  Indirect haemagglutination test for melioidosis.

Authors:  L R Ashdown
Journal:  Med J Aust       Date:  1987-10-05       Impact factor: 7.738

5.  Differentiation of Burkholderia species by PCR-restriction fragment length polymorphism analysis of the 16S rRNA gene and application to cystic fibrosis isolates.

Authors:  C Segonds; T Heulin; N Marty; G Chabanon
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

6.  Fatal human melioidosis in south-eastern Queensland.

Authors:  I A Scott; A M Bell; D R Staines
Journal:  Med J Aust       Date:  1997-02-17       Impact factor: 7.738

7.  Phylogenetic analysis of Ara+ and Ara- Burkholderia pseudomallei isolates and development of a multiplex PCR procedure for rapid discrimination between the two biotypes.

Authors:  T Dharakul; B Tassaneetrithep; S Trakulsomboon; S Songsivilai
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

8.  Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia.

Authors:  S D Aaron; W Ferris; D A Henry; D P Speert; N E Macdonald
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

9.  Human-to-human transmission of Pseudomonas pseudomallei.

Authors:  J B McCormick; D J Sexton; J G McMurray; E Carey; P Hayes; R A Feldman
Journal:  Ann Intern Med       Date:  1975-10       Impact factor: 25.391

10.  Rapid identification of some Leptospira isolates from cattle by random amplified polymorphic DNA fingerprinting.

Authors:  B G Corney; J Colley; S P Djordjevic; R Whittington; G C Graham
Journal:  J Clin Microbiol       Date:  1993-11       Impact factor: 5.948

View more
  27 in total

1.  Segregation is good for patients with cystic fibrosis.

Authors:  Steven Conway
Journal:  J R Soc Med       Date:  2008-07       Impact factor: 5.344

Review 2.  Laboratory diagnosis of melioidosis: past, present and future.

Authors:  Susanna K P Lau; Siddharth Sridhar; Chi-Chun Ho; Wang-Ngai Chow; Kim-Chung Lee; Ching-Wan Lam; Kwok-Yung Yuen; Patrick C Y Woo
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-22

3.  Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.

Authors:  Dominic Hill; Barbara Rose; Aniko Pajkos; Michael Robinson; Peter Bye; Scott Bell; Mark Elkins; Barbara Thompson; Colin Macleod; Shawn D Aaron; Colin Harbour
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

Review 4.  Clinical features and epidemiology of melioidosis pneumonia: results from a 21-year study and review of the literature.

Authors:  Ella M Meumann; Allen C Cheng; Linda Ward; Bart J Currie
Journal:  Clin Infect Dis       Date:  2011-11-04       Impact factor: 9.079

5.  The Brief Case: A Traveler's Tale-Burkholderia pseudomallei Infection in a Cystic Fibrosis Patient.

Authors:  I T Hettiarachchi; J Duckers; D Lau; R Dhillon
Journal:  J Clin Microbiol       Date:  2019-11-22       Impact factor: 5.948

Review 6.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

7.  Factors influencing acquisition of Burkholderia cepacia complex organisms in patients with cystic fibrosis.

Authors:  Kay A Ramsay; Claire A Butler; Stuart Paynter; Robert S Ware; Timothy J Kidd; Claire E Wainwright; Scott C Bell
Journal:  J Clin Microbiol       Date:  2013-09-18       Impact factor: 5.948

8.  Global transcriptional profiling of Burkholderia pseudomallei under salt stress reveals differential effects on the Bsa type III secretion system.

Authors:  Pornpan Pumirat; Jon Cuccui; Richard A Stabler; Joanne M Stevens; Veerachat Muangsombut; Ekapot Singsuksawat; Mark P Stevens; Brendan W Wren; Sunee Korbsrisate
Journal:  BMC Microbiol       Date:  2010-06-14       Impact factor: 3.605

9.  The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study.

Authors:  Bart J Currie; Linda Ward; Allen C Cheng
Journal:  PLoS Negl Trop Dis       Date:  2010-11-30

Review 10.  The art of persistence-the secrets to Burkholderia chronic infections.

Authors:  Eric R G Lewis; Alfredo G Torres
Journal:  Pathog Dis       Date:  2016-07-19       Impact factor: 3.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.